News - 04 Jan `23Update on Vitiligo Drug Development in 2023

New

Pune-based startup Ahammune Biosciences has recently completed the phase 1 clinical trials of its investigational new drug AB1001, being developed as a topical therapy for vitiligo. 

Dr T. Balganesh, Chairman of Ahammune’s Board said, “Vitiligo is a much neglected disease and specific treatments for the disease are not available. AB1001 is a novel class of compounds, discovered and developed at Ahammune, that has the potential to not only limit the progression of the disease but also reverses the pigmentation loss. The successful completion of Phase 1 of the molecule brings a much wanted treatment closer to the patients. We are looking forward to the compound becoming a drug shortly.”
 
Ahammune Biosciences and Ahmedabad-based Veeda Clinical Research had partnered for the first in human studies with Ahammune’s investigational new drug AB1001.

Source



      FAQOther Questions

      • Red Wine and Vitiligo

        Recent research has revealed intriguing findings about the potential protective effects of red wine against vitiligo, using a genetic approach to study health outcomes. Red Win...

      • Awareness Days Similar to World Vitiligo Day

        World Vitiligo Day, celebrated annually on June 25 since 2012, is a significant event dedicated to raising awareness about vitiligo and supporting those affected by the conditio...

      • How to get insurance coverage for vitiligo treatments?

        Getting insurance coverage for vitiligo treatments can be challenging, but there are several steps you can take to improve your chances For a more in-depth look, check out our ...